Article
Clinical Neurology
Anniina Snellman, Juan Lantero-Rodriguez, Andreja Emersic, Agathe Vrillon, Thomas K. Karikari, Nicholas J. Ashton, Milica Gregoric Kramberger, Sasa Cucnik, Claire Paquet, Uros Rot, Henrik Zetterberg, Kaj Blennow
Summary: The study develops new N-terminal-directed CSF total tau assays, which show increased levels ahead of standard t-tau in the Alzheimer's disease continuum, higher levels in patients with CJD or acute neurological diseases, and better potential as Alzheimer's disease blood biomarkers compared to Quanterix total tau.
Article
Biochemistry & Molecular Biology
Ioanna Tsantzali, Aikaterini Foska, Eleni Sideri, Evdokia Routsi, Effrosyni Tsomaka, Dimitrios K. Kitsos, Christina Zompola, Anastasios Bonakis, Sotirios Giannopoulos, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, George P. Paraskevas
Summary: CSF biomarkers are the gold standard for AD diagnosis, but plasma biomarkers may provide an alternative method with comparable accuracy and the advantage of avoiding lumbar puncture.
Review
Biochemistry & Molecular Biology
Sarah Holper, Rosie Watson, Nawaf Yassi
Summary: The advances in tau detection have revolutionized the diagnosis of neurodegenerative diseases, offering improved diagnostic accuracy and potential as a predictor of clinical progression and drug therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Juan Lantero-Rodriguez, Cecile Tissot, Anniina Snellman, Stijn Servaes, Andrea L. L. Benedet, Nesrine Rahmouni, Laia Montoliu-Gaya, Joseph Therriault, Wagner S. S. Brum, Jenna Stevenson, Firoza Z. Z. Lussier, Gleb Bezgin, Arthur C. C. Macedo, Mira Chamoun, Sulantha S. S. Mathotaarachi, Tharick A. A. Pascoal, Nicholas J. J. Ashton, Henrik Zetterberg, Pedro Rosa Neto, Kaj Blennow
Summary: This study evaluated the concentrations of N-terminal tau fragments (NTA-tau) in cerebrospinal fluid (CSF) and plasma using a novel immunoassay (NTA) in the TRIAD cohort. The results showed that CSF and plasma NTA-tau concentrations were specifically increased in cognitively impaired A beta-positive groups and displayed stronger correlations with tau positron emission tomography (PET) than with amyloid PET and magnetic resonance imaging (MRI). NTA-tau has potential as a tau tangle biomarker in clinical settings and trials.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Brian D. Hitt, Jaime Vaquer-Alicea, Victor A. Manon, Joshua D. Beaver, Omar M. Kashmer, Jan N. Garcia, Marc I. Diamond
Summary: Tau protein forms self-replicating assemblies that may contribute to the progression of Alzheimer's disease and related conditions. Improved biosensor cell lines, such as the v2H cells, have been developed to detect tau seeding activity in cerebrospinal fluid with greater sensitivity. However, the findings of tau seeding in AD patients' CSF have not been widely replicated.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2021)
Article
Neurosciences
Anna Lidia Wojdala, Davide Chiasserini, Giovanni Bellomo, Silvia Paciotti, Lorenzo Gaetani, Federico Paolini Paoletti, Lucilla Parnetti
Summary: Phosphatidylethanolamine binding protein 1 (PEBP1) has potential as a biomarker for Alzheimer's disease (AD), but further research is needed to evaluate its diagnostic potential.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Neurosciences
Soyeon Kim, Kiwon Kim, Kwangsik Nho, Woojae Myung, Hong-Hee Won
Summary: The study found a causal association between CSF biomarkers and the risk of LOAD, suggesting that the etiology of LOAD involves pathways of A beta and tau proteins. Further MR studies using large-scale data are needed to elucidate the pathophysiology of LOAD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
Ris E. Jansen, Sven J. van der Lee, Duber Gomez-Fonseca, Itziar de Rojas, Maria Carolina Dalmasso, Benjamin Grenier-Boley, Anna Zettergren, Aniket Mishra, Muhammad Ali, Victor Andrade, Celine Bellenguez, Luca Kleineidam, Fahri Kucukali, Yun Ju Sung, Niccolo Tesi, Ellen M. Vromen, Douglas P. Wightman, Daniel Alcolea, Montserrat Alegret, Ignacio Alvarez, Philippe Amouyel, Lavinia Athanasiu, Shahram Bahrami, Henri Bailly, Olivia Belbin, Sverre Bergh, Lars Bertram, Geert Jan Biessels, Kaj Blennow, Rafael Blesa, Merce Boada, Anne Boland, Katharina Buerger, Angel Carracedo, Laura Cervera-Carles, Genevieve Chene, Jurgen A. H. R. Claassen, Stephanie Debette, Jean-Francois Deleuze, Peter Paul de Deyn, Janine Diehl-Schmid, Srdjan Djurovic, Oriol Dols-Icardo, Carole Dufouil, Emmanuelle Duron, Emrah Duezel, Tormod Fladby, Juan Fortea, Lutz Froelich, Pablo Garcia-Gonzalez, Maria Garcia-Martinez, Ina Giegling, Oliver Goldhardt, Johan Gobom, Timo Grimmer, Annakaisa Haapasalo, Harald Hampel, Olivier Hanon, Lucrezia Hausner, Stefanie Heilmann-Heimbach, Seppo Helisalmi, Michael T. Heneka, Isabel Hernandez, Sanna-Kaisa Herukka, Henne Holstege, Jonas Jarholm, Silke Kern, Anne-Brita Knapskog, Anne M. Koivisto, Johannes Kornhuber, Teemu Kuulasmaa, Carmen Lage, Christoph Laske, Ville Leinonen, Piotr Lewczuk, Alberto Lleo, Adolfo Lopez de Munain, Sara Lopez-Garcia, Wolfgang Maier, Marta Marquie, Merel O. Mol, Laura Montrreal, Fermin Moreno, Sonia Moreno-Grau, Gael Nicolas, Markus M. Nothen, Adelina Orellana, Lene Palhaugen, Janne M. Papma, Florence Pasquier, Robert Perneczky, Oliver Peters, Yolande A. L. Pijnenburg, Julius Popp, Danielle Posthuma, Ana Pozueta, Josef Priller, Raquel Puerta, Ines Quintela, Inez Ramakers, Eloy Rodriguez-Rodriguez, Dan Rujescu, Ingvild Saltvedt, Pascual Sanchez-Juan, Philip Scheltens, Norbert Scherbaum, Matthias Schmid, Anja Schneider, Geir Selbaek, Per Selnes, Alexey Shadrin, Ingmar Skoog, Hilkka Soininen, Lluis Tarraga, Stefan Teipel, Betty Tijms, Magda Tsolaki, Christine Van Broeckhoven, Jasper Van Dongen, John C. van Swieten, Rik Vandenberghe, Jean-Sebastien Vidal, Pieter J. Visser, Jonathan Vogelgsang, Margda Waern, Michael Wagner, Jens Wiltfang, Mandy M. J. Wittens, Henrik Zetterberg, Miren Zulaica, Cornelia M. van Duijn, Maria Bjerke, Sebastiaan Engelborghs, Frank Jessen, Charlotte E. Teunissen, Pau Pastor, Mikko Hiltunen, Martin Ingelsson, Ole A. Andreassen, Jordi Clarimon, Kristel Sleegers, Agustin Ruiz, Alfredo Ramirez, Carlos Cruchaga, Jean-Charles Lambert, Wiesje van der Flier
Summary: This study found that levels of A beta 42 and pTau in cerebrospinal fluid are more direct indicators of the pathogenesis of Alzheimer's disease than clinical diagnosis. Through a collaborative effort, novel associations with AD risk loci and multiple biological pathways related to A beta 42 and pTau were identified.
ACTA NEUROPATHOLOGICA
(2022)
Article
Neurosciences
Johan Gobom, Andrea L. Benedet, Niklas Mattsson-Carlgren, Laia Montoliu-Gaya, Nina Schultz, Nicholas J. Ashton, Shorena Janelidze, Stijn Servaes, Mathias Sauer, Tharick A. Pascoal, Thomas K. Karikari, Juan Lantero-Rodriguez, Gunnar Brinkmalm, Henrik Zetterberg, Oskar Hansson, Pedro Rosa-Neto, Kaj Blennow
Summary: This study presents the first antibody-free mass spectrometric method for simultaneously measuring multiple phosphorylated epitopes in CSF tau, providing insights into the pathophysiology of Alzheimer's disease and potentially facilitating clinical trials for tau-based drug candidates.
MOLECULAR NEURODEGENERATION
(2022)
Article
Clinical Neurology
Kirsten E. J. Wesenhagen, Betty M. Tijms, Lynn Boonkamp, Patty L. Hoede, Julie Goossens, Nele Dewit, Philip Scheltens, Eugeen Vanmechelen, Pieter Jelle Visser, Charlotte E. Teunissen
Summary: This study investigated the potential processes related to p-tau subgroups in Alzheimer's disease (AD) and found that the biological heterogeneity in p-tau levels is related to amyloid metabolism and synaptic integrity independent of clinical stage.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Review
Neurosciences
Donovan A. McGrowder, Fabian Miller, Kurt Vaz, Chukwuemeka Nwokocha, Cameil Wilson-Clarke, Melisa Anderson-Cross, Jabari Brown, Lennox Anderson-Jackson, Lowen Williams, Lyndon Latore, Rory Thompson, Ruby Alexander-Lindo
Summary: This review presents the current evidence on CSF biomarkers for Alzheimer's disease, emphasizing the efficacy of existing core biomarkers and the need for further development of biomarkers reflecting other aspects of the disease mechanism. It also introduces new biomarkers that track Alzheimer's disease pathology and their potential in diagnosis and predicting cognitive decline.
Article
Clinical Neurology
Alexis Moscoso, Michel J. Grothe, Nicholas J. Ashton, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, Marc Suarez-Calvet, Henrik Zetterberg, Kaj Blennow, Michael Scholl
Summary: Measurement of tau phosphorylated at threonine 181 (p-tau181) in blood plasma is proposed as a specific biomarker for Alzheimer's disease. Longitudinal study reveals that plasma p-tau181 increases before amyloid-beta markers reach abnormal levels, correlating with amyloid-beta pathology. Plasma p-tau181 also shows associations with widespread cortical tau aggregation and may be a useful diagnostic and screening tool for Alzheimer's disease.
Article
Neurosciences
Andrea Pilotto, Marta Parigi, Giulio Bonzi, Beatrice Battaglio, Elisabetta Ferrari, Lorenza Mensi, Alberto Benussi, Salvatore Caratozzolo, Maura Cosseddu, Rosanna Turrone, Silvana Archetti, Nicholas J. Ashton, Henrik Zetterberg, Silvia Giliani, Alessandro Padovani
Summary: Plasma phosphorylated tau species levels are elevated in early stage AD and strongly related to phosphorylated tau, total tau, and amyloid in cerebrospinal fluid. These findings may support the use of plasma markers for diagnosing and prognosing AD in the early stage.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Giovanna Chaves Cavalcante, Leonardo Miranda Brito, Ana Paula Schaan, Andrea Ribeiro-dos-Santos, Gilderlanio Santana de Araujo
Summary: This study investigated the influence of mitochondrial genes and genetic variants on mild cognitive impairment and Alzheimer's Disease (AD). The findings suggest potential interactions involving mitochondrial genetics in the development and progression of AD, and identified specific molecular alterations as potential biomarkers for the disease.
Article
Biochemistry & Molecular Biology
Pei-Yang Gao, Ya-Nan Ou, Yi-Ming Huang, Zhi-Bo Wang, Yan Fu, Ya-Hui Ma, Qiong-Yao Li, Li-Yun Ma, Rui-Ping Cui, Yin-Chu Mi, Lan Tan, Jin-Tai Yu
Summary: Liver function may play a role in the progression of Alzheimer's disease. The study found that as AD progressed, certain liver function markers increased while others decreased. The relationship between liver function and CSF AD biomarkers indicates a potential mediation effect on cognition.
JOURNAL OF NEUROCHEMISTRY
(2024)
Article
Neurosciences
Karolina Minta, Gunnar Brinkmalm, Erik Portelius, Per Johansson, Johan Svensson, Petronella Kettunen, Anders Wallin, Henrik Zetterberg, Kaj Blennow, Ulf Andreasson
Summary: The study identified that the concentrations of brevican and neurocan peptides were significantly decreased in the cerebrospinal fluid of VaD patients, suggesting their potential as diagnostic biomarkers for VaD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Psychiatry
Maurits Johansson, Erik Stomrud, Philip S. Insel, Antoine Leuzy, Per Marten Johansson, Ruben Smith, Zahinoor Ismail, Shorena Janelidze, Sebastian Palmqvist, Danielle van Westen, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: The study revealed that in early-stage Alzheimer's disease, mild behavioral impairment is associated with tau pathology independently of memory deficits. This indicates that mild behavioral impairment is an important early clinical manifestation related to tau pathology in Alzheimer's disease.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Neurosciences
Ramita Dewan, Ruth Chia, Jinhui Ding, Richard A. Hickman, Thor D. Stein, Yevgeniya Abramzon, Sarah Ahmed, Marya S. Sabir, Makayla K. Portley, Arianna Tucci, Kristina Ibanez, F. N. U. Shankaracharya, Pamela Keagle, Giacomina Rossi, Paola Caroppo, Fabrizio Tagliavini, Maria L. Waldo, Per M. Johansson, Christer F. Nilsson, James B. Rowe, Luisa Benussi, Giuliano Binetti, Roberta Ghidoni, Edwin Jabbari, Coralie Viollet, Jonathan D. Glass, Andrew B. Singleton, Vincenzo Silani, Owen A. Ross, Mina Ryten, Ali Torkamani, Toshiko Tanaka, Luigi Ferrucci, Susan M. Resnick, Stuart Pickering-Brown, Christopher B. Brady, Neil Kowal, John A. Hardy, Vivianna Van Deerlin, Jean Paul Vonsattel, Matthew B. Harms, Huw R. Morris, Raffaele Ferrari, John E. Landers, Adriano Chio, J. Raphael Gibbs, Clifton L. Dalgard, Sonja W. Scholz, Bryan J. Traynor
Summary: Researchers analyzed whole-genome sequence data from 2,442 FTD/ALS patients, 2,599 LBD patients, and 3,158 neurologically healthy subjects, identifying pathogenic HTT gene expansions in a small percentage of FTD/ALS patients but not in the LBD or healthy groups. Postmortem evaluations supported an etiological relationship between HTT repeat expansions and FTD/ALS syndromes, suggesting the importance of genetic screening for HTT repeat expansions in FTD/ALS patients.
Correction
Multidisciplinary Sciences
Jacob W. Vogel, Yasser Iturria-Medina, Olof T. Strandberg, Ruben Smith, Elizabeth Levitis, Alan C. Evans, Oskar Hansson
NATURE COMMUNICATIONS
(2021)
Article
Neurosciences
Maurits Johansson, Erik Stomrud, Per Marten Johansson, Anna Svenningsson, Sebastian Palmqvist, Shorena Janelidze, Danielle van Westen, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: This study found that AD pathology in early stages of the disease is associated with the development of apathy and anxiety, independent of cognitive changes. The effects of A beta pathology on apathy are partially mediated by changes in cognitive performance.
BIOLOGICAL PSYCHIATRY
(2022)
Article
Multidisciplinary Sciences
Hanri Afghahi, Salmir Nasic, Bjoern Peters, Helena Rydell, Henrik Hadimeri, Johan Svensson
Summary: The study investigates the association between HbA1c variability and the risk of all-cause mortality in diabetic patients with PD. The results suggest that higher HbA1c variability is associated with increased risk of death in diabetic patients with PD.
Letter
Medicine, General & Internal
Henrik Ryberg, Per Johansson, Anders Wallin, Johan F. Emilsson, Elias Eriksson, Johan Svensson, Claes Ohlsson
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Muhammad M. Ali, Yun Ju Sung, Fengxian Wang, Maria Fernandez, John M. Morris, Anne Fagan, Kaj Blennow, Henrik Zetterberg, Amanda Heslegrave, Per Johansson, Johan Svensson, Bengt Nellgard, Alberto Lleo, Daniel Alcolea, Jordi Clarimon, Lorena Rami, Jose Luis Molinuevo, Marc Suarez-Calvet, Estrella R. Morenas-Rodriguez, Gernot J. Kleinberger, Christian Haass, Michael Ewers, Johannes Levin, Martin Farlow, Richard Perrin, Carlos Cruchaga
Summary: Two genetic variants in the KL gene are associated with Alzheimer's disease risk and may lower the incidence of neurodegeneration and cognitive decline.
Article
Endocrinology & Metabolism
Patrick Quinlan, Alexandra Horvath, Carl Eckerstrom, Anders Wallin, Johan Svensson
Summary: This study found that higher thyroid hormone levels were associated with lower brain volume and increased risk of Alzheimer's disease (AD) in elderly individuals. However, the relationship between serum thyroid hormones and hippocampal atrophy rates has not been previously investigated. The results showed that FT3/FT4 ratio was related to baseline hippocampal volume in all study groups, but only in AD patients, higher levels of thyroid hormones were associated with greater annual loss of hippocampal volume.
PSYCHONEUROENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Johan Svensson, Klara Sjogren, Lina Lawenius, Antti Koskela, Juha Tuukkanen, Karin H. Nilsson, Sofia Moverare-Skrtic, Claes Ohlsson
Summary: Insulin-like growth factor-I (IGF-I) levels and cortical bone dimensions play important roles in determining fracture risk in elderly people. Inactivation of liver-derived circulating IGF-I reduces periosteal bone expansion in young and older mice. This study investigates the effect of inducible inactivation of IGF-I specifically in bone on the bone phenotype in adult/old mice, finding that it results in reduced radial growth of cortical bone, suggesting the importance of locally derived IGF-I in regulating the cortical bone phenotype in older mice.
Article
Clinical Neurology
Petronella Kettunen, Maria Bjerke, Carl Eckerstrom, Michael Jonsson, Henrik Zetterberg, Kaj Blennow, Johan Svensson, Anders Wallin
Summary: We found that SSVD patients have a different biomarker profile, with lower levels of sAPP-β compared to AD patients and controls. We also observed signs of blood-brain barrier dysfunction in SSVD. These findings support the concept that SSVD is a distinct form of vascular cognitive disorder (VCD).
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2022)
Article
Clinical Neurology
Petronella Kettunen, Maria Bjerke, Carl Eckerstrom, Michael Jonsson, Henrik Zetterberg, Kaj Blennow, Johan Svensson, Anders Wallin
Summary: SSVD patients exhibit distinct biomarker profiles from AD and mixed AD/SSVD, with lower sAPP-β levels and blood-brain barrier dysfunction suggesting possible diagnostic tools for SSVD.
ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING
(2022)
